Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Dimethylphenylpiperazinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | APOBEC3A | P31941 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.96 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylphenylpiperazinium SCHEMBL3453554 | 0.98 | CHRNA7 (1.00) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Dimethylphenylpiperazinium SCHEMBL1427906 | 0.96 | CHRNA7 (0.96) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Dimethylphenylpiperazinium SCHEMBL6829257 | 0.96 | CHRNA7 (0.96) | MEN1POLBAPOBEC3APMP22KMT2A | |
| Iodide SCHEMBL404487 | 0.92 | MEN1 (0.85) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL10114942 | 0.90 | CHRNA7 (0.85) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL10105152 | 0.79 | CHRNA7 (0.72) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL6743986 | 0.77 | ALOX15 (0.64) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL10105155 | 0.76 | CHRNA7 (0.63) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL164538 | 0.75 | LMNA (0.67) | MEN1POLBAPOBEC3APMP22KMT2A | |
| SCHEMBL576454 | 0.75 | LMNA (0.67) | MEN1POLBAPOBEC3APMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331159-B2 | Polyesters and polyketoesters from carbonylative terpolymerization of enols, methods to produce, blends, and articles therefrom | EXXON MOBIL CHEMICAL PATENTS INC. (US) | 2025-06-17 | — | — | US | claimed |
| CN-119356472-A | Photovoltaic maximum power control method combining cubic spline interpolation and P & O improvement | 西南石油大学 | 2025-01-24 | — | — | CN | claimed |
| US-20240373736-A1 | Materials and Methods to Improve the Stability of Metal Halide Perovskites | THE UNIVERSITY OF TOLEDO (US) | 2024-11-07 | — | — | US | claimed |
| CN-115078490-B | Be used for detecting CN–Preparation method of iridium (III) complex sensitized NiO photocathode | 青岛科技大学 | 2024-04-30 | — | — | CN | claimed |
| US-11685755-B2 | Dicarbonyl ruthenium and osmium catalysts | Universita′ degli Studi di Udine (IT) | 2023-06-27 | — | — | US | claimed |
| CN-115078490-A | For detecting CN – Preparation method of iridium (III) complex sensitized NiO photocathode | 青岛科技大学 | 2022-09-20 | — | — | CN | claimed |
| US-20220064375-A1 | Polyesters and Polyketoesters from Carbonylative Terpolymerization of enols, Methods to Produce, Blends, and Articles Therefrom | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-03-03 | — | — | US | claimed |
| US-7914960-B2 | Additive containing charge transport layer photoconductors | XEROX CORPORATION (US) | 2011-03-29 | — | — | US | claimed |
| US-20090092913-A1 | ADDITIVE CONTAINING PHOTOGENERATING LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| US-20090092911-A1 | ADDITIVE CONTAINING CHARGE TRANSPORT LAYER PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| US-5861431-A | Incontinence treatment | IOTEK, INC. (US) | 1999-01-19 | — | — | US | claimed |
| EP-0831772-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0615855-B1 | Recording sheets containing pyridinium and/or piperazinum compounds | XEROX CORP (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996040054-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5441795-A | Piperazinium compounds | XEROX CORPORATION (US) | 1995-08-15 | — | — | US | claimed |
| EP-0615855-A1 | Recording sheets containing pyridinium and/or piperazinum compounds | XEROX CORPORATION (US) | 1994-09-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685755-B2 | Dicarbonyl ruthenium and osmium catalysts | OTC, ODC1, CBR3 | MEN1 3163/4885POLB 518/4885APOBEC3A 2584/4885 |
| US-20240373736-A1 | Materials and Methods to Improve the Stability of Metal Halide Perovskites | SOD1, BMI1, VCL | MEN1 250/4885POLB 2214/4885APOBEC3A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.